InfuSystem Q1 net rev $33.7M (-3% YoY); net income $1.0M vs prior loss

InfuSystem Holdings, Inc

2026-Q1 EPS reported $0.05 vs consensus $0.03 ▲ beat (+46.6%)

Patient Services rev $22.1M (+6% YoY); wound care revenue more than doubled to $2.1M.
Device Solutions rev $11.6M (-17% YoY) due to GE Healthcare contract restructure.
Gross margin expanded to 58.4% from 55.2%; adjusted EBITDA $6.4M (18.9% margin).
Full-year 2026 guidance reaffirmed: pro-forma net rev growth 6-8%, adj EBITDA margin mid-to-low 20%.
Repurchased $856k of common stock; liquidity $57.1M; new ERP went live March 1, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

InfuSystem Holdings, Inc reported first quarter ended March 31, 2026 results: revenue $33.7 million, net income $1.0 million, or $0.05 per diluted share, EPS $0.05 per diluted share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $33.7 million
Net income: $1.0 million, or $0.05 per diluted share
EPS: $0.05 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

InfuSystem Announces Financial Results for First Quarter 2026 Net Revenues of $33.7 million Representing a 3% Reduction from the Prior Year Net income of $1.0 million Adjusted EBITDA (non-GAAP) of $6.4 million Adjusted EBITDA (non-GAAP) margin expanded by 1% to 19% Reaffirms Full-Year 2026 Guidance

View on SEC.gov

Browse all earnings releases →

InfuSystem Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001628280-26-031649

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.